Clinical Advances in Hematology & Oncology最新文献

筛选
英文 中文
PARP inhibitors in metastatic prostate cancer: current evidence and future directions. PARP抑制剂在转移性前列腺癌中的作用:目前的证据和未来的方向。
IF 2
Kate McKendry, Corinne Maurice-Dror, Kim N Chi
{"title":"PARP inhibitors in metastatic prostate cancer: current evidence and future directions.","authors":"Kate McKendry, Corinne Maurice-Dror, Kim N Chi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Inhibitors of poly(ADP-ribose) polymerase (PARPis) are an established treatment for homologous recombination repair gene-altered metastatic prostate cancer. The efficacy of PARPis-both as single agents and in combination with androgen receptor pathway inhibitors (ARPIs)-was first established in patients with metastatic castration-resistant prostate cancer (mCRPC, more recently termed androgen pathway modulation-resistant [APMR] prostate cancer), with the greatest benefit observed in BRCA2-altered disease. This review focuses on the more recently demonstrated evidence of the benefit of PARPis in combination with standard-of-care ARPIs and androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC, also termed androgen pathway modulation-sensitive [APMS] prostate cancer) generated by the AMPLITUDE and TALAPRO-3 trials, which evaluated niraparib and talazoparib, respectively. How broadly PARPis will be incorporated into the clinical management of patients with mHSPC/APMS will depend on the perception of issues such as optimal patient eligibility (including biomarker selection), short- and long-term treatment-related adverse events, other available treatment options, and treatment sequencing. The review also examines future directions for PARPi therapy for the mHSPC/APMS disease state, including the ongoing EvoPAR-Prostate01 phase 3 registration trial evaluating the PARP1-selective agent saruparib.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8","pages":"487-498"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How I treat MDS/AML: individualizing therapy based on disease biology, patient fitness, molecular features, and treatment goals. 我如何治疗MDS/AML:基于疾病生物学、患者适应性、分子特征和治疗目标的个体化治疗。
IF 2
Courtney D DiNardo
{"title":"How I treat MDS/AML: individualizing therapy based on disease biology, patient fitness, molecular features, and treatment goals.","authors":"Courtney D DiNardo","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8 Suppl 12","pages":"1-12"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From ADAURA to LAURA: the evolving role of EGFR-targeted therapy in NSCLC. 从ADAURA到LAURA: egfr靶向治疗在非小细胞肺癌中的作用演变
IF 2
Kelsey Pan, Suresh S Ramalingam
{"title":"From ADAURA to LAURA: the evolving role of EGFR-targeted therapy in NSCLC.","authors":"Kelsey Pan, Suresh S Ramalingam","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Epidermal growth factor receptor gene (EGFR) mutations, most commonly involving exon 19 deletion or leucine-858-to-arginine substitution (L858R), define a biologically distinct subset of non-small cell lung cancers (NSCLCs). Third-generation EGFR tyrosine kinase inhibitors have transformed outcomes in metastatic disease, and this benefit has since been extended into localized and locally advanced NSCLC through 3 landmark randomized trials: ADAURA, which established adjuvant osimertinib as standard of care after the resection of stage IB-IIIA disease; NeoADAURA, which demonstrated improved pathologic responses with neoadjuvant osimertinib in resectable stage II-IIIB disease; and LAURA, which established osimertinib consolidation after chemoradiation in unresectable stage III disease. Together, these trials mark a shift away from the mutation-agnostic treatment paradigms that previously guided the treatment of earlier stages of NSCLC toward targeted therapy across curative-intent settings. This review summarizes the evidence supporting perioperative and consolidation EGFR tyrosine kinase inhibitor therapy in resectable and unresectable locally advanced EGFR-mutant NSCLC, and it addresses practical considerations including treatment sequencing, the management of radiation-related toxicity, and central nervous system surveillance. It also examines unresolved questions, including the optimal duration of adjuvant and consolidation therapy, the role of circulating tumor DNA in guiding treatment decisions, and the management of atypical EGFR mutations, which remain outside the evidence base guiding current guidelines. As precision oncology extends further into curative-intent settings, molecular selection is becoming central to treatment planning in locally advanced NSCLC.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8","pages":"529-535"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic approaches in aRCC: focus on patient selection for IO-IO vs IO-TKI. aRCC的治疗方法:侧重于患者选择IO-IO vs IO-TKI。
IF 2
Wenxin Xu
{"title":"Therapeutic approaches in aRCC: focus on patient selection for IO-IO vs IO-TKI.","authors":"Wenxin Xu","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8 Suppl 13","pages":"1-12"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Approval versus coverage: the differences between FDA and CMS standards. 批准与覆盖:FDA和CMS标准之间的差异。
IF 2
David Hyman
{"title":"Approval versus coverage: the differences between FDA and CMS standards.","authors":"David Hyman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8","pages":"511-513"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lessons and limitations of the PARADIGM trial in acute myeloid leukemia. 急性髓性白血病的PARADIGM试验的教训和局限性。
IF 2
Hagop M Kantarjian
{"title":"Lessons and limitations of the PARADIGM trial in acute myeloid leukemia.","authors":"Hagop M Kantarjian","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8","pages":"514-516"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PNH management: a clinical case of ravulizumab-danicopan combination therapy. ravulizumab-danicopan联合治疗PNH 1例。
IF 2
Ilene C Weitz
{"title":"PNH management: a clinical case of ravulizumab-danicopan combination therapy.","authors":"Ilene C Weitz","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 7 Suppl 9","pages":"1-13"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant RCC and recurrence after adjuvant immunotherapy. 辅助免疫治疗后的辅助RCC和复发。
IF 2
Wenxin Xu
{"title":"Adjuvant RCC and recurrence after adjuvant immunotherapy.","authors":"Wenxin Xu","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 7 Suppl 11","pages":"2-4"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment after progression and emerging sequencing strategies. 进展后的治疗和新兴的测序策略。
IF 2
Pedro C Barata
{"title":"Treatment after progression and emerging sequencing strategies.","authors":"Pedro C Barata","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 7 Suppl 11","pages":"7-9"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision medicine in advanced hormone receptor-positive breast cancer: integrating genomic profiling and liquid biopsy into clinical practice. 晚期激素受体阳性乳腺癌的精准医疗:将基因组分析和液体活检纳入临床实践。
IF 2
Devashish Desai, Parth Sampat, Gowthami Koorapati, Prashanth Ashok Kumar, Abirami Sivapiragasam
{"title":"Precision medicine in advanced hormone receptor-positive breast cancer: integrating genomic profiling and liquid biopsy into clinical practice.","authors":"Devashish Desai, Parth Sampat, Gowthami Koorapati, Prashanth Ashok Kumar, Abirami Sivapiragasam","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Precision medicine has reshaped the management of advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer by coupling treatment with tumor genomics rather than clinicopathologic features alone. In this review, we highlight the role of next-generation sequencing (NGS) in our clinical practice. We summarize the performance characteristics of various NGS platforms and outline the available techniques of NGS. We also describe clinically relevant genomic alterations and targeted treatments.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 7","pages":"465-475"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书